About the Company
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SELB News
Selecta Biosciences files for $200M mixed shelf
Selecta Biosciences (NASDAQ:SELB) Wednesday filed a prospectus for a mixed shelf offering of up to $200 million. This prospectus is not an offer to sell these securities. SEC Filing Selecta ...
Sanofi, Selecta sign $900m deal to develop food allergy therapies
Sanofi has entered into a strategic global collaboration with Selecta Biosciences, Inc., a clinical-stage biopharmaceutical US company that is developing a new class of synthetic vaccines and ...
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Needham initiated coverage on Cartesian Therapeutics Inc (NASDAQ:RNAC), a private ... reverse merger/ private placement financing with Selecta Biosciences. Cartesian is developing re-dosable ...
Flagship Ventures 2007 General Partner LLC's Net Worth
Inc., and SELECTA BIOSCIENCES INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive ...
Earl Sands's Net Worth
Earl Sands does not have any significant net worth to report based on the numbers we have. This is based on reported shares in SELECTA BIOSCIENCES INC.
Cartesian Therapeutics Inc (RNAC)
WATERTOWN - Selecta Biosciences (NASDAQ:SELB), a biotech company based in ... Investors following Cartesian Therapeutics, Inc. (NASDAQ:RNAC) might be interested to learn that Timothy A. Springer, a ...
Arcadia Biosciences Inc RKDA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Sagimet Biosciences Inc. (SGMT)
April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to ...
TKPHF Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...
Forte Biosciences Inc Ordinary Shares FBRX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Pulse Biosciences, Inc. (PLSE)
HAYWARD, Calif., April 24, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ...
TKPHF Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...
Loading the latest forecasts...